Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Follicular 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hereditary Sensory and Autonomic Neuropathies 2Squamous Cell Carcinoma of Head and Neck 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hematologic Neoplasms 1Head and Neck Neoplasms 1

Interventions

Fulvestrant 3Alpelisib 3duvelisib 2Cetuximab 2volagidemab 1talazoparib 1ruxolitinib 1parsaclisib 1olaparib 1obinutuzumab 1lorlatinib 1encorafenib 1dapagliflozin 1cobimetinib 1chiauranib 1binimetinib 1avelumab 1Vemurafenib 1SF 1126 1Rituximab 1NVP-BKM120 1Drug Therapy 1CYH33 1Aspirin 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Hereditary Sensory and Autonomic Neuropathies × duvelisib × Clear all
NCT02204982 2023-09-28

DYNAMO + R

SecuraBio

Phase 3 Terminated
13 enrolled 10 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Hereditary Sensory and Autonomic Neuropathies

NCT02292225 2023-02-27

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

SecuraBio

Phase 1 Terminated
3 enrolled
LymphoidOther hematologic neoplasm

Hereditary Sensory and Autonomic Neuropathies, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡